Previous Article | Next Article 
Antimicrobial Agents and Chemotherapy, September 1999, p. 2222-2224, Vol. 43, No. 9
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Introduction of a norA Promoter Region
Mutation into the Chromosome of a Fluoroquinolone-Susceptible Strain of
Staphylococcus aureus Using Plasmid Integration
Glenn W.
Kaatz,1,2,*
Susan M.
Seo,2 and
Timothy J.
Foster3
The John D. Dingell Department of Veteran's
Affairs Medical Center1 and the
Department of Internal Medicine, Division of Infectious Diseases,
Wayne State University School of Medicine,2
Detroit, Michigan 48201, and Microbiology Department, Moyne
Institute of Preventive Medicine, Trinity College, Dublin 2, Ireland3
Received 19 October 1998/Returned for modification 24 November
1998/Accepted 29 June 1999
 |
ABSTRACT |
It has been postulated that a mutation 11 bp 3' to the
10 motif
of the norA promoter is involved in the increased
expression of the gene observed in some strains of Staphylococcus
aureus exhibiting efflux-related fluoroquinolone resistance.
Introduction of this mutation into the chromosome of a
fluoroquinolone-susceptible strain by plasmid integration resulted in
the minimum inhibitory concentrations of NorA substrates being
increased, fluoroquinolone uptake being reduced, and norA
expression being enhanced. Diffuse hybridization of norA
and integrating vector probes at a similar molecular weight range,
higher than that of the norA transcript, was observed in
the integrant, suggesting the possibility of a plasmid-based promoter
contributing to norA expression. The ratio of the quantity
of this transcript, which was also observed in the parent strain of the
integrant, to the quantity of primary norA transcript was
0.14, demonstrating that it was unlikely that this mRNA species
contributed significantly to the results observed. It is more likely
that the introduced promoter region mutation does affect the expression
of norA.
 |
INTRODUCTION |
A number of mechanisms by which
Staphylococcus aureus develops resistance to fluoroquinolone
antimicrobial agents have been described. Selected mutations in the
grlA and gyrA genes, encoding the A subunits of
topoisomerase IV and DNA gyrase, respectively, and in the
gyrB gene (encoding the B subunit of DNA gyrase) correlate with fluoroquinolone resistance (3-6, 16, 20, 21). Up
regulation of norA, a naturally occurring gene which encodes
a membrane-based multidrug efflux transporter (NorA), also results in
raised fluoroquinolone minimum inhibitory concentrations (MICs)
(7). These mechanisms can occur singly or in combination,
with fluoroquinolone susceptibility generally decreasing as mutations
accumulate (4, 9).
It has been shown that some strains that have increased expression of
norA have a point mutation in the promoter region of that
gene (7, 15). It has been postulated that this mutation, which lies 11 bp 3' to the
10 motif, is responsible for up regulating norA expression. We investigated this possibility by using
plasmid integration to introduce such a mutation into the chromosome of a fluoroquinolone-susceptible S. aureus strain.
 |
MATERIALS AND METHODS |
Bacterial strains and plasmids.
SA-1199 is a methicillin-
and fluoroquinolone-susceptible clinical isolate of S. aureus. SA-1199B is a fluoroquinolone-resistant mutant of this
strain, recovered during ciprofloxacin therapy of experimental
endocarditis, that has been shown to possess a grlA mutation
in addition to having increased norA expression (7,
9). SA-RN4220 is a fluoroquinolone-susceptible
restriction-deficient mutant of S. aureus 8325-4 that
readily accepts DNA propagated in Escherichia coli
(10). E. coli DH10B was used as the
host organism for the propagation of plasmids (12). The
plasmid vector utilized for chromosomal integration was
pG+Host6, a 6.7-kb construct that possesses erythromycin
(EM) and ampicillin resistance markers and can replicate in both
S. aureus and E. coli (13). The
S. aureus replicon in pG+Host6 is temperature sensitive.
Determination of antimicrobial susceptibilities.
Unless
otherwise noted, all antimicrobial agents and other reagents used were
of the highest grade available and were obtained from their respective
manufacturers or were purchased from Sigma Chemical Co., St. Louis, Mo.
MIC testing was performed with a microdilution technique and
cation-adjusted Mueller-Hinton II broth (BBL Microbiology Systems,
Cockeysville, Md.) according to the guidelines of the National
Committee for Clinical Laboratory Standards (14). The effect
of reserpine (final concentration, 20 µg/ml) on selected MICs was
also determined.
PCR procedures.
We have shown that SA-1199B has a T
A
transversion 11 bp 3' to the
10 motif of the norA promoter
(7). PCR was employed to amplify a fragment that included
this position. The primers used were
5'-TACATTCAACGGTACCTTCGCCTT-3' (forward), which
introduced an artificial KpnI site (underlined), and
5'-TAACGTACCACCGAATGGCG-3' (reverse). Parameters for PCR
were 94°C (1 min), 55°C (1 min), and 72°C (0.5 min) for 30 cycles. This produced a 461-bp product which then was digested with
KpnI and HindII, leaving a 367-bp fragment.
This fragment was cloned into pG+Host6 digested with
KpnI and SmaI, producing pK120 (7.1 kb), which then was transformed into E. coli DH10B by
standard techniques (1).
Plasmid integration.
pG+Host6 and pK120 were
recovered from E. coli DH10B and were purified
by cesium chloride density-gradient centrifugation (1). These plasmids were electrotransformed into SA-RN4220, with propagation of recipient strains at 28°C on Luria-Bertani (LB) agar plates containing 10 µg of erythromycin (LB-EM) per ml. Selected
EM-resistant colonies were shown to contain either pG+Host6
or pK120 by using a miniprep procedure (17). Randomly selected transformants then were grown in 10 ml of LB broth containing 10 µg of EM/ml at 28°C overnight. A 1:100 dilution of this culture was plated onto the same medium and was grown for 2.5 h at 28°C, followed by a shift in the incubation temperature to 39°C for 3 h. The higher temperature inhibits independent plasmid replication and
favors integration of pK120 via a single crossover event into the site
of homology within the chromosome. Serial dilutions were made onto
LB-EM, and the plates were incubated at 37°C overnight. No
EM-resistant colonies were recovered from SA-RN4220 transformed with
pG+Host6 following exposure to the higher temperature,
indicating that nonspecific plasmid integration did not occur. The
absence of pK120 in EM-resistant colonies of SA-RN4220 originally
transformed with this plasmid was verified by miniprep analysis. One
such isolate (SA-K1606) was chosen for further study.
Southern and Northern blotting.
Chromosomal DNA from
SA-RN4220 and SA-K1606 was isolated and digested with EcoRV,
for which there are no sites in either norA or pK120.
Fragments were separated in an agarose gel and transferred to a nylon
membrane. Southern hybridization was carried out with probes specific
for norA and pG+Host6 (19).
Protoplasts of SA-RN4220 and SA-K1606 were produced by exposing
organisms to lysostaphin (30 µg/ml) in SMM buffer (0.5 M sucrose, 0.014 M sodium maleate, 0.02 M MgCl2, pH 6.8) for 45 min on
ice (9). Total RNA was isolated by the method of Chomczynski
(2). RNA (30 µg) from each strain was applied to and
separated in a formaldehyde-containing agarose gel. The RNA was
transferred to a nylon membrane, and hybridization with a
norA probe produced by PCR from SA-RN4220 was carried out
under high-stringency conditions (42°C, 50% formamide)
(19). The procedure was repeated with a 341-bp
AseI fragment of pG+Host6, which originates just
proximal to the integration site, as a probe.
DNA sequence determination.
The nucleotide sequence of the
norA region of SA-K1606 was determined by using the dideoxy
chain-termination method with primers located within
pG+Host6 and norA, but outside of the presumed
site of recombination in norA (18).
Transcription initiation and mRNA quantification.
The 5'
termini of the norA mRNAs of all strains examined in this
study were mapped by primer extension with a commercially available kit
(1) (Promega Corp., Madison, Wis.). The quantity of
transcript present was estimated by using a phosphorimaging system
according to the manufacturer's guidelines (Molecular Dynamics, Inc.,
Sunnyvale, Calif.).
Uptake of [14C]enoxacin.
Uptake studies were
performed in quadruplicate with whole cells as described previously
(8). [14C]enoxacin (specific activity, 15.9 µCi/mg) was provided by Parke-Davis Pharmaceutical Research, Ann
Arbor, Mich. Carbonyl cyanide m-chlorophenylhydrazone (CCCP)
(final concentration, 100 µM) was used to dissipate the proton motive
force across the cytoplasmic membrane.
Statistics.
Comparison of [14C]enoxacin uptake
data was performed by using the rank sum test. A p value of
less than 0.05 was considered significant.
 |
RESULTS AND DISCUSSION |
Southern hybridization revealed that the norA and
pG+Host6 probes hybridized with an EcoRV
fragment of the same size in SA-K1606 (~10.1 kb) (Fig.
1). This fragment is larger than that
observed with the norA probe and native SA-RN4220 DNA by an
amount approximately equal to the size of the integrating plasmid. Only
the norA probe hybridized with SA-RN4220 DNA (3.4-kb
fragment). These data indicated that the vector did integrate into the
targeted region of the chromosome. A determination of the nucleotide
sequence of the norA region of SA-K1606 confirmed that
integration had occurred as expected. The norA promoter of
SA-1199B that had been cloned into pG+Host6 was found to be
present in place of the wild-type SA-RN4220 norA promoter,
and pG+Host6 was upstream of this. The norA gene
itself was completely intact. The difference in the intensity of the
hybridization signals generated by the norA and
pG+Host6 probes is likely due to the fact that the
norA probe used in this experiment was produced from
SA-1199B by PCR. There is a moderate degree of sequence variance in the
region targeted by the probe between SA-RN4220 and SA-1199B (68 mismatches with the 790-bp probe).

View larger version (38K):
[in this window]
[in a new window]
|
FIG. 1.
Southern analysis of chromosomal DNA digested with
EcoRV. Lanes 1 and 3, SA-RN4220; lanes 2 and 4, SA-K1606.
The norA probe was used in lanes 1 and 2, and the
pG+Host6 probe was used in lanes 3 and 4. The positions of
molecular mass markers are indicated, with size in kDa given on the
left.
|
|
The MICs of various NorA substrates for SA-RN4220 and SA-K1606 are
shown in Table 1. At the concentration
employed, reserpine did not inhibit the growth of either organism (MIC
of reserpine for each organism was greater than 100 µg/ml). The
presence of the integrated plasmid resulted in a two- to fourfold rise
in MICs, which for enoxacin, norfloxacin, and ethidium bromide was reversible by reserpine. The uptake of [14C]enoxacin was
significantly reduced in SA-K1606 between 0.5 and 15 min, with the
exception of the 1.3- and 3-min time points (Fig. 2). The addition of CCCP disrupted drug
efflux and eliminated the uptake difference between the strains.

View larger version (15K):
[in this window]
[in a new window]
|
FIG. 2.
[14C]enoxacin uptake profiles (mean ± standard error). CCCP (final concentration, 100 µM) was added at
the indicated time. , SA-RN4220; , SA-K1606.
|
|
By using the norA probe it can be seen that, compared to
SA-RN4220, SA-K1606 produces an increased quantity of norA
transcript (Fig. 3). The identity of the
more-defined signal of the highest molecular weight that is observed in
all lanes (including the SA-1199B lane) is unknown. This signal is
always observed in analyses of the norA mRNA of SA-1199 and
SA-1199B (8).

View larger version (63K):
[in this window]
[in a new window]
|
FIG. 3.
Northern analysis. Lane 1, SA-K1606; lane 2, SA-RN4220;
lane 3, SA-1199B. The position of norA mRNA is indicated.
|
|
The diffuse signal seen just above that of the norA
transcript in SA-K1606 is also observed with SA-RN4220 (Fig. 3, lane 2; more visible on the original autoradiogram) and in approximately the
same location (but less diffuse) with SA-1199B RNA (Fig. 3, lane 3).
These signals, as well as the more-defined signal noted above, may
represent larger transcripts including norA. Such
transcripts may originate upstream of norA or may begin with
norA and include downstream sequences. Diffuse hybridization
in this region was also observed by using the pG+Host6
probe in SA-K1606 (data not shown), suggesting the possibility of a
plasmid-based promoter contributing to the increased expression of
norA observed in this organism.
Primer extension analysis revealed two transcripts that included
norA in all strains and which were present in varying
quantities. The 5' terminus of the most abundant of the two mapped to
93 bp upstream of the norA initiation codon and 7 bp
downstream of the
10 promoter motif (data not shown). Such a start
site is typical, and this species likely represents the primary
norA transcript (11). This transcript was 10- and
12-fold more abundant in SA-K1606 and SA-1199B than in the respective
parent strains. The 5' terminus of the second species mapped to 194 bp
upstream of the norA coding region. In SA-K1606 and
SA-1199B, the quantity of this transcript was only 14 and 2% that of
the primary norA transcript, respectively. Computer-based
analysis of the region immediately upstream from the start site of this
mRNA species, which included no pG+Host6 sequences,
revealed no promoter-like motifs.
Our data do not provide conclusive evidence that the quantity of the
secondary transcript is increased due to the activity of a
plasmid-based promoter, but the possibility cannot be dismissed based
on the Northern analysis results observed with the norA and
pG+Host6 probes. However, the fact that this mRNA species
is detected in SA-RN4220 and SA-1199 and accounts for only a minor
proportion of the norA-containing transcripts in SA-K1606
makes it unlikely that it is a factor that contributes significantly to
the results observed. Rather, the data presented here strongly suggest
that the T
A norA promoter region mutation found in
SA-1199B does play a role in efflux-mediated multidrug resistance.
There is an 8-bp, perfectly inverted repeat encompassing the
10 motif
of the norA promoter which may serve as a binding site for a
protein regulating the expression of the gene (7, 9). We
have preliminary evidence that a protein(s) recognizing the
norA promoter region does exist (data not shown). It is
conceivable that promoter region mutations may affect the binding of a
regulatory protein to its recognition site, leading to altered
norA expression. However, such a mutation is not required
for increased expression of norA. We have described an
S. aureus strain (SA-1199-3) displaying inducible up
regulation of norA and a wild-type promoter region
nucleotide sequence (8). It is possible that in this
situation a mutational alteration of the putative regulatory protein
itself has occurred, affecting norA expression. Clearly,
further work is necessary to more completely characterize the processes
involved in norA regulation.
 |
ACKNOWLEDGMENTS |
This study was supported by VA Medical Research funds.
We thank E. Manguin for providing pG+Host6.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: The John D. Dingell Department of Veteran's Affairs Medical Center, the Department of Internal Medicine, Division of Infectious Diseases, Wayne State University School of Medicine, Detroit, MI 48201. Phone: (313) 576-4487. Fax: (313) 576-1112. E-mail: gkaatz{at}juno.com.
 |
REFERENCES |
| 1.
|
Ausubel, F. M.,
R. Brent,
R. E. Kingston,
D. D. Moore,
J. G. Seidman,
J. A. Smith, and K. Struhl.
1995.
Current protocols in molecular biology.
John Wiley and Sons, Inc., New York, N.Y.
|
| 2.
|
Chomczynski, P.
1993.
A reagent for the single-step simultaneous isolation of RNA, DNA, and proteins from cell and tissue samples.
BioTechniques
15:532-535[Medline].
|
| 3.
|
Ferrero, L.,
B. Cameron,
B. Manse,
D. Lagneaux,
J. Crouzet,
A. Famechon, and F. Blanche.
1994.
Cloning and primary structure of Staphylococcus aureus DNA topoisomerase IV: a primary target of fluoroquinolones.
Mol. Microbiol.
13:641-653[Medline].
|
| 4.
|
Ferrero, L.,
B. Cameron, and J. Crouzet.
1995.
Analysis of gyrA and grlA mutations in stepwise-selected ciprofloxacin-resistant mutants of Staphylococcus aureus.
Antimicrob. Agents Chemother.
39:1554-1558[Abstract].
|
| 5.
|
Goswitz, J. J.,
K. E. Willard,
C. E. Fasching, and L. R. Peterson.
1992.
Detection of gyrA gene mutations in methicillin-resistant Staphylococcus aureus: analysis by polymerase chain reaction and automated direct DNA sequencing.
Antimicrob. Agents Chemother.
36:1166-1169[Abstract/Free Full Text].
|
| 6.
|
Ito, H.,
H. Yoshida,
M. Bogaki-Shonai,
T. Niga,
H. Hattori, and S. Nakamura.
1994.
Quinolone resistance mutations in the DNA gyrase gyrA and gyrB genes of Staphylococcus aureus.
Antimicrob. Agents Chemother.
38:2014-2023[Abstract/Free Full Text].
|
| 7.
|
Kaatz, G. W.,
S. M. Seo, and C. A. Ruble.
1993.
Efflux-mediated fluoroquinolone resistance in Staphylococcus aureus.
Antimicrob. Agents Chemother.
37:1086-1094[Abstract/Free Full Text].
|
| 8.
|
Kaatz, G. W., and S. M. Seo.
1995.
Inducible NorA-mediated multidrug resistance in Staphylococcus aureus.
Antimicrob. Agents Chemother.
39:2650-2655[Abstract].
|
| 9.
|
Kaatz, G. W., and S. M. Seo.
1997.
Mechanisms of fluoroquinolone resistance in genetically related strains of Staphylococcus aureus.
Antimicrob. Agents Chemother.
41:2733-2737[Abstract].
|
| 10.
|
Kreiswirth, B. N.,
S. Lofdahl,
M. J. Betley,
M. O'Reilly,
P. M. Schlievert,
M. S. Bergdoll, and R. P. Novick.
1983.
The toxic shock syndrome exotoxin structural gene is not detectably transmitted by prophage.
Nature
305:709-712[Medline].
|
| 11.
|
Lewin, B.
1990.
Genes, vol. IV.
Oxford University Press, New York, N.Y.
|
| 12.
|
Lorow, D., and J. Jessee.
1990.
Focus
12:19.
|
| 13.
|
Maguin, E.,
H. Prevost,
S. Dusko Ehrlich, and A. Gruss.
1996.
Efficient insertional mutagenesis in lactococci and other gram-positive bacteria.
J. Bacteriol.
178:931-935[Abstract/Free Full Text].
|
| 14.
|
National Committee for Clinical Laboratory Standards.
1997.
Approved standard M7-A4. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 4th ed.
National Committee for Clinical Laboratory Standards, Villanova, Pa.
|
| 15.
|
Ng, E. Y.,
M. Trucksis, and D. C. Hooper.
1994.
Quinolone resistance mediated by norA: physiologic characterization and relationship to flqB, a quinolone resistance locus on the Staphylococcus aureus chromosome.
Antimicrob. Agents Chemother.
38:1345-1355[Abstract/Free Full Text].
|
| 16.
|
Ng, E. Y.,
M. Trucksis, and D. C. Hooper.
1996.
Quinolone resistance mutations in topoisomerase IV: relationship to the flqA locus and genetic evidence that topoisomerase IV is the primary target and DNA gyrase the secondary target of fluoroquinolones in Staphylococcus aureus.
Antimicrob. Agents Chemother.
40:1881-1888[Abstract].
|
| 17.
|
Novick, R. P.
1991.
Genetic systems in staphylococci.
Methods Enzymol.
204:587-636[Medline].
|
| 18.
|
Sanger, F.,
S. Nicklen, and A. R. Coulson.
1977.
DNA sequencing with chain-terminating inhibitors.
Proc. Natl. Acad. Sci. USA
74:5463-5467[Abstract/Free Full Text].
|
| 19.
|
Southern, E. M.
1975.
Detection of specific sequences among DNA fragments separated by gel electrophoresis.
J. Mol. Biol.
98:503-517[Medline].
|
| 20.
|
Sreedharan, S.,
M. Oram,
B. Jensen,
L. R. Peterson, and L. M. Fisher.
1990.
DNA gyrase gyrA mutations in ciprofloxacin-resistant strains of Staphylococcus aureus: close similarity with quinolone resistance mutations in Escherichia coli.
J. Bacteriol.
172:7260-7262[Abstract/Free Full Text].
|
| 21.
|
Yamagishi, J.,
T. Kojima,
Y. Oyamada,
K. Fujimoto,
H. Hattori,
S. Nakamura, and M. Inoue.
1996.
Alterations in the DNA topoisomerase IV grlA gene responsible for fluoroquinolone resistance in Staphylococcus aureus.
Antimicrob. Agents Chemother.
40:1157-1163[Abstract].
|
Antimicrobial Agents and Chemotherapy, September 1999, p. 2222-2224, Vol. 43, No. 9
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Mima, T., Kohira, N., Li, Y., Sekiya, H., Ogawa, W., Kuroda, T., Tsuchiya, T.
(2009). Gene cloning and characteristics of the RND-type multidrug efflux pump MuxABC-OpmB possessing two RND components in Pseudomonas aeruginosa. Microbiology
155: 3509-3517
[Abstract]
[Full Text]
-
Kumar, A., Khan, I. A., Koul, S., Koul, J. L., Taneja, S. C., Ali, I., Ali, F., Sharma, S., Mirza, Z. M., Kumar, M., Sangwan, P. L., Gupta, P., Thota, N., Qazi, G. N.
(2008). Novel structural analogues of piperine as inhibitors of the NorA efflux pump of Staphylococcus aureus. J Antimicrob Chemother
61: 1270-1276
[Abstract]
[Full Text]
-
Vidaillac, C., Guillon, J., Arpin, C., Forfar-Bares, I., Ba, B. B., Grellet, J., Moreau, S., Caignard, D.-H., Jarry, C., Quentin, C.
(2007). Synthesis of Omeprazole Analogues and Evaluation of These as Potential Inhibitors of the Multidrug Efflux Pump NorA of Staphylococcus aureus. Antimicrob. Agents Chemother.
51: 831-838
[Abstract]
[Full Text]
-
Poole, K.
(2005). Efflux-mediated antimicrobial resistance. J Antimicrob Chemother
56: 20-51
[Abstract]
[Full Text]
-
Kaatz, G. W., Thyagarajan, R. V., Seo, S. M.
(2005). Effect of Promoter Region Mutations and mgrA Overexpression on Transcription of norA, Which Encodes a Staphylococcus aureus Multidrug Efflux Transporter. Antimicrob. Agents Chemother.
49: 161-169
[Abstract]
[Full Text]
-
Grkovic, S., Brown, M. H., Skurray, R. A.
(2002). Regulation of Bacterial Drug Export Systems. Microbiol. Mol. Biol. Rev.
66: 671-701
[Abstract]
[Full Text]
-
O'Neill, A. J., Chopra, I.
(2002). Insertional inactivation of mutS in Staphylococcus aureus reveals potential for elevated mutation frequencies, although the prevalence of mutators in clinical isolates is low. J Antimicrob Chemother
50: 161-169
[Abstract]
[Full Text]
-
Raherison, S., Gonzalez, P., Renaudin, H., Charron, A., Bebear, C., Bebear, C. M.
(2002). Evidence of Active Efflux in Resistance to Ciprofloxacin and to Ethidium Bromide by Mycoplasma hominis. Antimicrob. Agents Chemother.
46: 672-679
[Abstract]
[Full Text]
-
Poole, K.
(2000). Efflux-Mediated Resistance to Fluoroquinolones in Gram-Positive Bacteria and the Mycobacteria. Antimicrob. Agents Chemother.
44: 2595-2599
[Full Text]